

Financial Tear Sheet

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

Stock Quote


ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$9.14
Change (%)	-0.06 (0.65%)
Volume	73,970

Data as of March 21, 2018 10:18 a.m. ET

Minimum 20 minute delay

[Refresh quote](#)

Stock Chart



Press Releases

March 14, 2018

[Aduro Biotech Announces Upcoming Data Presentations at the 2018 American Association for Cancer Research Annual Meeting](#)

March 14, 2018

[Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference](#)

Events & Presentations

March 21, 2018

[Aduro Biotech Inc at the 28th Annual Oppenheimer Healthcare Conference](#)

Data Provided by Thomson Reuters